Global Markets for Vaccine Technologies

Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.

Report Includes

• An overview of the global market for human and animal (veterinary) vaccines and related vaccine technologies.
• Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
• Examination of current and future strategies within the human and animal (veterinary) vaccines markets, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines.
• A breakdown of the seven major categories of vaccines broken down by market shares belonging to leading manufacturers and/or suppliers.
• Discussion of human and animal (veterinary) vaccines as to their prophylactic or therapeutic use, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, and travel vaccines.

Global sales of human and animal vaccines reached approximately $25.2 billion in 2009. The market is expected to rise at a compound annual growth rate (CAGR) of 17.9% to reach $64.2 billion by 2015.

• The global market for vaccines is expected to reach $22.4 billion by the end of 2008. It should reach $36.3 billion by 2013, a com¬pound annual growth rate (CAGR) of nearly 11%.
• Although pediatric vaccines traditionally have had the largest share of the market, adult and therapeutic vaccines will likely usurp this position in the near future.
• Patent activity has heightened to an almost frenzied level over the study period, with as many as 250 each year for 2006 and 2007.

• The total worldwide market for prophylactic and therapeutic vaccines is estimated to be $5.8 billion in 2001.
• Growing at an average annual rate (AAGR) of 11.6%, this market is expected to approach $10 billion in 2006.
• Pediatric prophylactic vaccines make up 58% of the current market, but will show the slowest growth, at an AAGR of 8.7% through 2006.
• Adult prophylactic vaccines are the second largest group with sales of nearly $2.4 billion in 2001 and are expected to rise at an AAGR of 10.1% to more than $3.8 billion in 2006.
• Therapeutic vaccines will feature growth of more than 100% on average per year through the period, but by 2006 will still make up only 10.5% of the market.